Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EMC
Global X Emerging Markets Great Consumer ETF
$36.85
-0.5%
$36.65
$27.88
$39.30
$65.23M0.8412,117 shs3,630 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
C$0.00
C$7.13
C$590.00
C$317.06MN/A8,002 shs921 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EMC
Global X Emerging Markets Great Consumer ETF
0.00%-5.37%-1.80%+24.22%+26.99%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EMC
Global X Emerging Markets Great Consumer ETF
$36.85
-0.5%
$36.65
$27.88
$39.30
$65.23M0.8412,117 shs3,630 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
C$0.00
C$7.13
C$590.00
C$317.06MN/A8,002 shs921 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EMC
Global X Emerging Markets Great Consumer ETF
0.00%-5.37%-1.80%+24.22%+26.99%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EMC
Global X Emerging Markets Great Consumer ETF
2.65
Moderate Buy$36.24-1.66% Downside
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EMC
Global X Emerging Markets Great Consumer ETF
N/AN/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
C$39.91M0.00N/A3.94C$6.07 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EMC
Global X Emerging Markets Great Consumer ETF
N/A$1.0734.44N/AN/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/A-C$63.06N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
EMC
Global X Emerging Markets Great Consumer ETF
$0.240.65%N/A22.43%N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EMC
Global X Emerging Markets Great Consumer ETF
N/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
37.47
4.06
3.66

Institutional Ownership

CompanyInstitutional Ownership
EMC
Global X Emerging Markets Great Consumer ETF
79.86%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
EMC
Global X Emerging Markets Great Consumer ETF
N/A1.77 millionN/ANot Optionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
48723.31 millionN/ANot Optionable

Recent News About These Companies

Rethinking rare diseases: treat the whole patient
Panetta Institute for Public Policy
2024 Breakthrough Prizes in Life Sciences
TMC Life Sciences Bhd (TMCN)
Life Sciences Learning Community
Chicago Life Sciences Summit
College of Liberal Arts & Sciences
WEF, Telangana joins hands to start thematic centre on healthcare and life sciences
Working on PLI schemes for more sectors: Piyush Goyal
TSX:CVE (CENOVUS ENERGY INC.)

Global X Emerging Markets Great Consumer ETF NYSEARCA:EMC

$36.85 -0.18 (-0.49%)
As of 12:57 PM Eastern

The Global X Emerging Markets Great Consumer ETF (EMC) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that invests in companies across multiple sectors that are positioned to benefit from the increasing consumption and growing purchasing power of consumers from the emerging markets. EMC was launched on Sep 24, 2010 and is managed by Global X.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

ProMetic Life Sciences stock logo

ProMetic Life Sciences TSE:PLI

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.